Author:
Reetu Reetu,Garg Aakriti,Roy Kuldeep K.,Roy Anupam,Gupta Sreya,Malakar Chandi C.
Reference18 articles.
1. a) H. King, R.E. Aubert, W.H. Herman, Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431. b) A.D. Seftel, P. Sun, R. Swindle, The Prevalence of Hypertension, Hyperlipidemia, Diabetes Mellitus and Depression in Men with Erectile Dysfunction, J. Urol. 171 (2004) 2341-2345.
2. a) V. Saini, Molecular mechanisms of insulin resistance in type 2 diabetes mellitus, World J. Diabetes 1 (2010) 68-75. b) A.J. Scheen, Pathophysiology of Type 2 Diabetes, ActaClin.Belg. 58 (2003) 335-341. c) M. Hernandez-Quiles, M.F. Broekema, E. Kalkhoven, PPAR gamma in metabolism, immunity, and cancer: Unified and diverse mechanisms of action, Front. Endocrinol. 12 (2021).
3. The Mechanisms of Action of PPARs;Berger;Annu. Rev. Med.,2002
4. a) M. Moreno, A. Lombardi, E. Silvestri, R. Senese, F. Cioffi, F. Goglia, A. Lanni, P.D. Lange, PPARs: Nuclear Receptors Controlled by, and Controlling, Nutrient Handling through Nuclear and Cytosolic Signaling, PPAR Res. 2010 (2010) 1-10. b) G. Krey, O. Braissant, F. L’Horset, E. Kalkhoven, M. Perroud, M.G. Parker, W. Wahli, Fatty Acids, Eicosanoids, and Hypolipidemic Agents Identified as Ligands of Peroxisome Proliferator-Activated Receptors by Coactivator-Dependent Receptor Ligand Assay, Mol. Endocrinol. 11 (1997) 779-791.
5. M. Heald, M.A. Cawthorne, Dual Acting and Pan-PPAR Activators as Potential Anti-diabetic Therapies, Handb. Exp. Pharmacol. 203 (2011) 35-51. b) B. Guru, A.K. Tamrakar, S.P. Mandal, P.B. Kumar, A. Sharma, S.N. Manjula, A Novel Partial PPARγ Agonist Has Weaker Lipogenic Effect in Adipocytes and Stimulates GLUT4 Translocation in Skeletal Muscle Cells via AMPK-Dependent Signaling, Pharmacology 106 (2021) 1-2.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献